Research progress of B7-H3 in malignant tumors
B7 homolog 3 (B7-H3, also known as CD276) is a novel member of the B7 immune protein family. There is a marked difference in the expression and distribution of B7-H3 protein and mRNA between normal and tumor tissues, with widespread expression in tumor tissues and a close relationship with tumor pro...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1586759/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849690002093506560 |
|---|---|
| author | Shuaixiang Zhao Shuaixiang Zhao He Zhang Guanning Shang Guanning Shang |
| author_facet | Shuaixiang Zhao Shuaixiang Zhao He Zhang Guanning Shang Guanning Shang |
| author_sort | Shuaixiang Zhao |
| collection | DOAJ |
| description | B7 homolog 3 (B7-H3, also known as CD276) is a novel member of the B7 immune protein family. There is a marked difference in the expression and distribution of B7-H3 protein and mRNA between normal and tumor tissues, with widespread expression in tumor tissues and a close relationship with tumor progression. B7-H3 activates or inhibits tumor immune responses by binding to receptors on the surface of immune cells. Apart from participating in tumor immune activities, it has regulatory effects on non-immunological functions, such as tumor migration and invasion, angiogenesis, glycometabolism, and drug resistance. Thus, it has important biological functions in regulating the progression of malignant tumors. Current research on the structure, function, and therapeutic methods of B7-H3 is continuously breaking new ground, deepening our understanding of B7-H3, and promoting the development of therapeutic drugs targeting this new protein. This review briefly discusses the structure and distribution of B7-H3, as well as its immune and non-immune functions in the progression of cancer. It also summarizes the research progress on drugs targeting B7-H3 and the latest developments in clinical trials, highlighting their significant potential for the treatment of malignant tumors. |
| format | Article |
| id | doaj-art-f902e2ef3a974edd8a211319927a702b |
| institution | DOAJ |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-f902e2ef3a974edd8a211319927a702b2025-08-20T03:21:27ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-05-011610.3389/fimmu.2025.15867591586759Research progress of B7-H3 in malignant tumorsShuaixiang Zhao0Shuaixiang Zhao1He Zhang2Guanning Shang3Guanning Shang4Department of Bone and Soft Tissue Oncology, Department of Orthopaedic, Shengjing Hospital, China Medical University, Shenyang, Liaoning, ChinaThe First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, ChinaDepartment of Bone and Soft Tissue Oncology, Department of Orthopaedic, Shengjing Hospital, China Medical University, Shenyang, Liaoning, ChinaDepartment of Bone and Soft Tissue Oncology, Department of Orthopaedic, Shengjing Hospital, China Medical University, Shenyang, Liaoning, ChinaThe First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, ChinaB7 homolog 3 (B7-H3, also known as CD276) is a novel member of the B7 immune protein family. There is a marked difference in the expression and distribution of B7-H3 protein and mRNA between normal and tumor tissues, with widespread expression in tumor tissues and a close relationship with tumor progression. B7-H3 activates or inhibits tumor immune responses by binding to receptors on the surface of immune cells. Apart from participating in tumor immune activities, it has regulatory effects on non-immunological functions, such as tumor migration and invasion, angiogenesis, glycometabolism, and drug resistance. Thus, it has important biological functions in regulating the progression of malignant tumors. Current research on the structure, function, and therapeutic methods of B7-H3 is continuously breaking new ground, deepening our understanding of B7-H3, and promoting the development of therapeutic drugs targeting this new protein. This review briefly discusses the structure and distribution of B7-H3, as well as its immune and non-immune functions in the progression of cancer. It also summarizes the research progress on drugs targeting B7-H3 and the latest developments in clinical trials, highlighting their significant potential for the treatment of malignant tumors.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1586759/fullB7-H3(CD276)malignant tumortargeted therapyimmunitydrug trials |
| spellingShingle | Shuaixiang Zhao Shuaixiang Zhao He Zhang Guanning Shang Guanning Shang Research progress of B7-H3 in malignant tumors Frontiers in Immunology B7-H3(CD276) malignant tumor targeted therapy immunity drug trials |
| title | Research progress of B7-H3 in malignant tumors |
| title_full | Research progress of B7-H3 in malignant tumors |
| title_fullStr | Research progress of B7-H3 in malignant tumors |
| title_full_unstemmed | Research progress of B7-H3 in malignant tumors |
| title_short | Research progress of B7-H3 in malignant tumors |
| title_sort | research progress of b7 h3 in malignant tumors |
| topic | B7-H3(CD276) malignant tumor targeted therapy immunity drug trials |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1586759/full |
| work_keys_str_mv | AT shuaixiangzhao researchprogressofb7h3inmalignanttumors AT shuaixiangzhao researchprogressofb7h3inmalignanttumors AT hezhang researchprogressofb7h3inmalignanttumors AT guanningshang researchprogressofb7h3inmalignanttumors AT guanningshang researchprogressofb7h3inmalignanttumors |